Higher body fat content at baseline in patients with ankylosing spondylitis (AS) is likely to weaken response to treatment with tumour necrosis factor-α (TNF-α) blockers, measured by the Ankylosing Spondylitis Disease Activity Score containing C-reactive protein (ASDAS-CRP) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), suggests a recent study.
Among ageing adult congenital heart disease (ACHD) patients, traditional atherosclerotic risk factors are associated with coronary artery disease (CAD), while ischaemic stroke is related to factors suggesting a cardioembolic aetiology, a multicentre case–control study has found.
Age appears to not significantly impact treatments and outcomes for hepatocellular carcinoma (HCC), a new study reveals. Survival is comparable between older and younger patients, and equally active treatments should be administered to both age groups.
Etanercept therapy for a period of 5 years leads to small changes in serum lipid concentrations, which are inversely correlated with inflammatory markers, according to a recent study. Other cardiovascular disease (CVD) risk factors remain stable.
There is a need for at least 2 consecutive years of 4-month aerobic interval training to chronically enhance metabolic syndrome (MetS; z score), a recent study has found. Blood pressure (BP) that does not fully revert to pretraining values mediates this chronic effect, allowing a cumulative improvement.
Post-traumatic stress disorder (PTSD) occurring within a year after childbirth via vaginal delivery is not rare, being strongly associated with bad memories of delivery at day 2 postpartum, a study has found.
The addition of the glucagon-like peptide-1 analogue semaglutide to standard of care resulted in sustained reduction in weight and waist circumference in individuals with type 2 diabetes (T2D) with high cardiovascular risk, according to the phase III SUSTAIN 6* trial presented at EASD 2017.
An 8-week regimen of sofosbuvir-velpatasvir-voxilaprevir combination is not noninferior to a 12-week regimen of sofosbuvir-velpatasvir for patients with chronic hepatitis C virus (HCV) infection, report two recent phase 3 open-label trials.
The additional use of intermittent low-energy diet (LED) or daily meal replacements after a mean 10-percent weight loss and 1-year maintenance effectively maintains weight loss in obese patients with knee osteoarthritis for 3 years, according to a recent study.